CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 7 enrolled
Drug / intervention
Rivastigmine (RLD) transdermal patch +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03915626
NCT03915626Early Ph 1Completed
CompareCT.gov

Determination of Serum Rivastigmine Levels After Using Rivastigmine Transdermal Delivery Systems With and Without Standardized Heat Application in Healthy Human Volunteers

University of Maryland, Baltimore·interventional·Posted Apr 16, 2019·Updated Apr 4, 2022

In Brief

A Early Phase 1 clinical trial evaluating Rivastigmine (RLD) transdermal patch and Rivastigmine (generic) transdermal patch for Bioavailability. Completed, enrolled 7 participants across 1 site.

Detailed Summary

This research study is designed to measure the amount of medicine in blood over time after the patch is placed on the skin with and without external heat application.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBioavailability
CountriesUnited States
CollaboratorsFood and Drug Administration (FDA)

Timeline

Early Ph 1CompletedFinished
2020202120222023202420252026
First PostedApr 16, 2019
Enrollment StartOct 4, 2019
Primary CompletionMay 4, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.2 years ago

Interventions

Rivastigmine (RLD) transdermal patchdrug

brand name patch

Rivastigmine (generic) transdermal patchdrug

generic patch